<DOC>
	<DOCNO>NCT00832884</DOCNO>
	<brief_summary>To evaluate safety IV Lacosamide child partial-onset epilepsy , age 4-35 year old , inclusive , either unable take oral medication require intravenous administration IV Lacosamide .</brief_summary>
	<brief_title>The Safety Intravenous Lacosamide</brief_title>
	<detailed_description>Lacosamide tablets intravenous formulation approve United States fall 2008 . Lacosamide indicate use adjunctive therapy treatment partial onset seizure disorder patient ' age seventeen year older . A parenteral dosage form Lacosamide desirable patient temporarily unable take medication orally . The objective study evaluate safety IV Lacosamide child epilepsy , age 4 35 year , either unable take oral medication , parenteral administration IV Lacosamide desirable .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Patients must diagnosis epilepsy receive antiepileptic drug therapy prior initiation IV Lacosamide Patients must medical condition parenteral administration Lacosamide desirable . Patients may male female . Patients must 4 year age old , less age 35 year . Patient / legally authorize representative must sign informed consent form prior study specific procedure . Patients exclude entry study follow true : Patient previously participate intravenous Lacosamide study . Patient status epilepticus within last 3 month . Patient history drug allergy Lacosamide . Patient pregnant . Patient take experimental drug within last 30 day . Patient significant hepatic renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>partial</keyword>
	<keyword>onset</keyword>
	<keyword>epilepsy</keyword>
	<keyword>pediatric</keyword>
	<keyword>lacosamide</keyword>
	<keyword>partial onset epilepsy</keyword>
	<keyword>vimpat</keyword>
</DOC>